1
|
Ganem D and Prince AM: Hepatitis B virus
infection - natural history and clinical consequences. New Engl J
Med. 350:1118–1129. 2004. View Article : Google Scholar
|
2
|
Shepard CW, Simard EP, Finelli L, Fiore AE
and Bell BP: Hepatitis B virus infection: epidemiology and
vaccination. Epidemiol Rev. 28:112–125. 2006. View Article : Google Scholar : PubMed/NCBI
|
3
|
Raney AK, Hamatake RK and Hong Z: Agents
in clinical development for the treatment of chronic hepatitis B.
Expert Opin Investig Drugs. 12:1281–1295. 2003. View Article : Google Scholar : PubMed/NCBI
|
4
|
Rehermann B: Immune responses in hepatitis
B virus infection. Semin Liver Dis. 23:21–38. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kakimi K, Isogawa M, Chung J, Sette A and
Chisari FV: Immunogenicity and tolerogenicity of hepatitis B virus
structural and nonstructural proteins: implications for
immunotherapy of persistent viral infections. J Virol.
76:8609–8620. 2002. View Article : Google Scholar : PubMed/NCBI
|
6
|
Steinman RM and Hemmi H: Dendritic cells:
translating innate to adaptive immunity. Curr Top Microbiol
Immunol. 311:17–58. 2006.PubMed/NCBI
|
7
|
Pozzi LA, Maciaszek JW and Rock KL: Both
dendritic cells and macrophages can stimulate naive CD8 T cells in
vivo to proliferate, develop effector function, and differentiate
into memory cells. J Immunol. 175:2071–2081. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Almand B, Resser JR, Lindman B, et al:
Clinical significance of defective dendritic cell differentiation
in cancer. Clin Cancer Res. 6:1755–1766. 2000.PubMed/NCBI
|
9
|
Glickman MH and Ciechanover A: The
ubiquitin-proteasome proteolytic pathway: destruction for the sake
of construction. Physiol Rev. 82:373–428. 2002.PubMed/NCBI
|
10
|
Shabek N and Ciechanover A: Degradation of
ubiquitin: the fate of the cellular reaper. Cell Cycle. 9:523–530.
2010. View Article : Google Scholar : PubMed/NCBI
|
11
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
|
12
|
Warnatsch A, Bergann T and Krüger E:
Oxidation matters: the ubiquitin proteasome system connects innate
immune mechanisms with MHC class I antigen presentation. Mol
Immunol. 55:106–109. 2013. View Article : Google Scholar
|
13
|
Burr ML, Boname JM and Lehner PJ: Studying
ubiquitination of MHC class I molecules. Methods Mol Biol.
960:109–125. 2013.PubMed/NCBI
|
14
|
Schödel F, Moriarty AM, Peterson DL, et
al: The position of heterologous epitopes inserted in hepatitis B
virus core particles determines their immunogenicity. J Virol.
66:106–114. 1992.PubMed/NCBI
|
15
|
Singh TR, Garland MJ, Cassidy CM, et al:
Microporation techniques for enhanced delivery of therapeutic
agents. Recent Pat Drug Deliv Formul. 4:1–17. 2010. View Article : Google Scholar
|
16
|
Kim D, Jeon C, Kim JH, et al: Cytoplasmic
transduction peptide (CTP): new approach for the delivery of
biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res.
312:1277–1288. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Huang Y, Chen Z, Jia H, Wu W, Zhong S and
Zhou C: Induction of Tc1 response and enhanced cytotoxic T
lymphocyte activity in mice by dendritic cells transduced with
adenovirus expressing HBsAg. Clin Immunol. 119:280–290. 2006.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Tatu RF, Anuşca DN, Groza SŞ, et al:
Morphological and functional characterization of femoral head
drilling-derived mesenchymal stem cells. Rom J Morphol Embryol.
55:1415–1422. 2014.
|
19
|
Crawford TQ, Ndhlovu LC, Tan A, et al:
HIV-1 infection abrogates CD8+ T cell mitogen-activated protein
kinase signaling responses. J Virol. 85:12343–12350. 2011.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Chen JH, Yu YS, Chen XH, Liu HH, Zang GQ
and Tang ZH: Enhancement of CTLs induced by DCs loaded with
ubiquitinated hepatitis B virus core antigen. World J
Gastroenterol. 18:1319–1327. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Giermasz AS, Urban JA, Nakamura Y, et al:
Type-1 polarized dendritic cells primed for high IL-12 production
show enhanced activity as cancer vaccines. Cancer Immunol
Immunother. 58:1329–1336. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wang L, Zou ZQ, Liu CX and Liu XZ:
Immunotherapeutic interventions in chronic hepatitis B virus
infection: a review. J Immunol Methods. 407:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Tsai SL, Sheen IS, Chien RN, et al:
Activation of Th1 immunity is a common immune mechanism for the
successful treatment of hepatitis B and C: tetramer assay and
therapeutic implications. J Biomed Sci. 10:120–135. 2003.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Phillips S, Chokshi S, Riva A, Evans A,
Williams R and Naoumov NV: CD8(+) T cell control of hepatitis B
virus replication: direct comparison between cytolytic and
noncytolytic functions. J Immunol. 184:287–295. 2010. View Article : Google Scholar
|
25
|
Schliehe C, Bitzer A, van den Broek M and
Groettrup M: Stable antigen is most effective for eliciting
CD8+ T-cell responses after DNA vaccination and
infection with recombinant vaccinia virus in vivo. J Virol.
86:9782–9793. 2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Chiang CL, Balint K, Coukos G and
Kandalaft LE: Potential approaches for more successful dendritic
cell-based immunotherapy. Expert Opin Biol Ther. Jan 2–2015.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
27
|
Tavakoli S, Mederacke I, Herzog-Hauff S,
et al: Peripheral blood dendritic cells are phenotypically and
functionally intact in chronic hepatitis B virus (HBV) infection.
Clin Exp Immunol. 151:61–70. 2008. View Article : Google Scholar
|
28
|
Op den Brouw ML, Binda RS, van Roosmalen
MH, et al: Hepatitis B virus surface antigen impairs myeloid
dendritic cell function: a possible immune escape mechanism of
hepatitis B virus. Immunology. 126:280–289. 2009. View Article : Google Scholar :
|
29
|
Chen HZ, Wu CP, Chao YC and Liu CY:
Membrane penetrating peptides greatly enhance baculovirus
transduction efficiency into mammalian cells. Biochem Biophys Res
Commun. 405:297–302. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Schaefer A, Nethe M and Hordijk PL:
Ubiquitin links to cytoskeletal dynamics, cell adhesion and
migration. Biochem J. 442:13–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Gao G and Luo H: The ubiquitin-proteasome
pathway in viral infections. Can J Physiol Pharmacol. 84:5–14.
2006. View
Article : Google Scholar : PubMed/NCBI
|
32
|
Wang QM, Kang L and Wang XH: Improved
cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA
vaccine against Mycobacterium tuberculosis. Microbiol Immunol.
53:384–390. 2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Pal A and Donato NJ: Ubiquitin-specific
proteases as therapeutic targets for the treatment of breast
cancer. Breast Cancer Res. 16:4612014. View Article : Google Scholar
|
34
|
Rodriguez F, Zhang J and Whitton JL: DNA
immunization: ubiquitination of a viral protein enhances cytotoxic
T-lymphocyte induction and antiviral protection but abrogates
antibody induction. J Virol. 71:8497–8503. 1997.PubMed/NCBI
|
35
|
Cao T, Lazdina U, Desombere I, et al:
Hepatitis B virus core antigen binds and activates naive human B
cells in vivo: studies with a human PBL-NOD/SCID mouse model. J
Virol. 75:6359–6366. 2001. View Article : Google Scholar : PubMed/NCBI
|
36
|
Chen W, Shi M, Shi F, et al: HBcAG-pulsed
dendritic cell vaccine induces Th1 polarization and production of
hepatitis B virus-specific cytotoxic T lymphocytes. Hepatol Res.
39:355–365. 2009. View Article : Google Scholar : PubMed/NCBI
|